Actavis Receives Approval of Levetiracetam Oral Solution in the U.S.

MORRISTOWN, N.J., Jan. 21 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Levetiracetam Oral Solution. Distribution of the product has commenced. Levetirac...

Lupin is Granted USFDA Approval for Levetiracetam Tablets

BALTIMORE, Jan. 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval for the Company's Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750mg and 1000mg from the U.S. Food and Drug Administration (USFDA). Commercia...

Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution

COLUMBUS, Ohio, Jan. 15 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of their Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250mg, 500mg, 750mg, 1000mg, and Oral Solution 100mg/mL. The product is available for immediate shipment to wholesalers and...

Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB

PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL ) today announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into an agreement to settle pending litigation with UCB Societe Anonyme and UCB Pharma Inc. (collectively, UCB) relating to Levetiracetam Tab...

New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures

...XR(TM) is the only extended-release formulation of levetiracetam and cannot be substituted with generic levetiracetam, immediate-release levetiracetam or any other antiepileptic medication at the pharm...ociety meeting demonstrated that taking two 750 mg levetiracetam extended-release tablets is the same as taking thr...

New research suggests common anti-seizure medications may increase risk of cardiovascular problems

...e of those two drugs who were being switched over to one of two newer anti-seizure drugs which do not widely affect enzymes lamotrigine (Lamictal) or levetiracetam (Keppra). The goal was to determine if the change affected the patients' cholesterol levels and other key markers of cardiovascular disease. Just...

FDA Adds Suicide Warning to Epilepsy Drugs

...R, Depakene); ethosuximide (Zarontin); ethotoin (Peganone); felbamate (Felbatol); gabapentin (Neurontin); lamotrigine (Lamictal); lacosamide (Vimpat); levetiracetam (Keppra); mephenytoin (Mesantoin); methosuximide (Celontin); oxcarbazepine (Trileptal); pregabalin (Lyrica); primidone (Mysoline); tiagabine (Gabitril...

Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately

...or its Abbreviated New Drug Application (ANDA) for levetiracetam Tablets, 250 mg, 500 mg and 750 mg. levetiracetam Tablets are the generic version of UCB Pharma's Ke...agreement to settle pending litigation relating to levetiracetam Tablets. Pursuant to the settlement, Mylan was giv...

FDA Advisers Don't Back 'Black Box' Warning for Epilepsy Drugs

... Carbatrol, Equetro, Tegretol, Tegretol XR), Felbamate (marketed as Felbatol), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), Pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed a...

FDA Advisers Don't Back Epilepsy Drug Warnings

... Carbatrol, Equetro, Tegretol, Tegretol XR), Felbamate (marketed as Felbatol), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), Pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed a...

Levetiracetam in Medical Technology

New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures

...nded-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional...08 AES Annual Meeting Safety Profile of levetiracetam Extended Release Compared to Immediate Release: An...erability advantages versus the same daily dose of levetiracetam IR. According to the meta-analysis, patients takin...

Keppra XR(TM) Extended-Release Tablets Filed with the FDA

...cacy, safety, and tolerability of extended-release levetiracetam tablets (2x500 mg) once-daily as adjunctive therap... of partial onset seizures in the extended-release levetiracetam group was 46.1% compared to 33.4% with placebo dur...ents in the placebo group. In the extended-release levetiracetam group 10.1% of patients had 100% reduction in part...

UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets

...cacy, safety, and tolerability of extended-release levetiracetam tablets (2x500 mg) once-daily as adjunctive therap... of partial onset seizures in the extended-release levetiracetam group was 46.1% compared to 33.4% with placebo dur...ents in the placebo group. In the extended-release levetiracetam group 10.1% of patients had 100% reduction in part...

Levetiracetam in Medical Dictionary

Tremor

...s, while others have ... Tremor ... Article: Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDs. Article: The effect of levetiracetam on tremor severity and ... Tremor is generally caused by problems in parts of the brain or spinal cord that ... Essential tremor may be acco...

Partial

...e. ... Given two partial rankings over n elements, and with b and c equiva ... Dr. Tracy Glauser presents his most recent findings on the use of levetiracetam (Keppra) as an adjunctive (add-on) treatment for children with partial onset seizures. Find articles about Teeth and hundreds of other health-...

Levetiracetam in Biological Technology

Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008

...fset by unfavorable pricing. Products launched during calendar year 2008 contributed revenues of $264.0 million, with paroxetine extended-release and levetiracetam accounting for the majority. Total calendar year 2008 third-party revenues for EMEA, Asia Pacific and Specialty were $1.52 billion, $537.4 millio...

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

...ent with placebo) -- Lamotrigine (33.3 percent vs. 18.3 percent) -- levetiracetam (37.6 percent vs. 17.6 percent) -- Valproate (45.3 percent vs. 21.3 per... percent placebo) -- Lamotrigine (34.2 percent vs. 19.0 percent) -- levetiracetam (43.4 percent vs. 19.4 percent) -- Valproate (47.5 percent vs. 26.9 per...

US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)

... study evaluating the efficacy and tolerability of levetiracetam oral solution (20-50 mg/kg/day) in 116 pediatric p...tment with one or two other antiepileptic drugs. levetiracetam was shown to significantly reduce the frequency of... with 19.6% of placebo-treated patients (p=0.013). levetiracetam was generally well-tolerated in this pediatric pop...